Verrica Pharmaceuticals Inc. (VRCA) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
- BOJ eyeing September rate hike, faster pace of tightening, sources say
Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
August 14, 2024 7:45 AM EDT- Reports YCANTH® revenue, net of $4.9M for second quarter of 2024 along with the expansion of YCANTHs distribution footprint to include Cencora, Inc. as a specialty distributor
-Â Announces positive preliminary topline results of Phase 2 clinical study of VP-315 for the treatment of patients with basal cell carcinoma
-Â Continues to progress preparation for global Phase 3 Common Warts trial with initiation expected in 1H 2025
-Â Conference Call Scheduled for Today at 8:30 am ETÂ
WEST CHESTER, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc.... More
